1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/23071
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTektonidou, M. G.en
dc.contributor.authorPetrovas, C. A.en
dc.contributor.authorIoannidis, J. P.en
dc.contributor.authorVlachoyiannopoulos, P. G.en
dc.contributor.authorMoutsopoulos, H. M.en
dc.date.accessioned2015-11-24T19:30:20Z-
dc.date.available2015-11-24T19:30:20Z-
dc.identifier.issn0014-2972-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23071-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntibodies, Anticardiolipin/*blooden
dc.subjectAntibody Specificityen
dc.subjectAntiphospholipid Syndrome/epidemiology/*immunologyen
dc.subjectEnzyme-Linked Immunosorbent Assay/methodsen
dc.subjectFemaleen
dc.subjectGlycoproteins/immunologyen
dc.subjectHumansen
dc.subjectImmunoglobulin G/blooden
dc.subjectImmunoglobulin M/blooden
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectOdds Ratioen
dc.subjectPhosphatidylcholines/immunologyen
dc.subjectPlatelet Activating Factor/*immunologyen
dc.subjectScleroderma, Systemic/epidemiology/immunologyen
dc.subjectSeroepidemiologic Studiesen
dc.subjectThrombosis/epidemiology/immunologyen
dc.subjectbeta 2-Glycoprotein Ien
dc.titleClinical importance of antibodies against platelet activating factor in antiphospholipid syndrome manifestationsen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/10886305-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2000-
heal.abstractBACKGROUND: We assessed whether antibodies against platelet activating factor (PAF) are related to the presence of antiphospholipid syndrome (APS) clinical manifestations, in particular thrombosis, in patients with connective tissue diseases. MATERIALS AND METHODS: Anti-PAF, anticardiolipin (aCL), antibeta2 glycoprotein I (antibeta2GPI) and antiphosphatidylcholine (anti-PC) antibodies were determined in 52 patients with APS, 29 patients with systemic lupus erythematosus (SLE) aCL but without APS, 30 patients with SLE without aCL, and 30 patients with scleroderma. A new enzyme-linked immunosorbent assay (ELISA) was developed for determining anti-PAF antibodies in a bovine serum-free fashion. RESULTS: The ELISA showed high specificity. Homologous inhibition experiments showed 60-70% inhibition. Anti-PAF antibodies were found in 18/52 APS patients, 10/29 SLE/aCL+ patients, 9/30 SLE/aCL- patients and 3/30 scleroderma patients. Anti-PAF antibodies were significantly associated with anti-PC antibodies (odds ratio [OR] 12. 7, P < 0.01), and there was a modest association with immunoglobulin G (IgG) aCL (OR 3.1, P > 0.10), but not with IgM aCL or antibeta2GPI. Three SLE/aCL+ patients and five SLE/aCL- patients had clinical manifestations characteristic of APS. All these patients had anti-PAF antibodies, while none had high titres of aCL or antibeta2GPI antibodies and only one had anti-PC antibodies. Among the combined APS and SLE groups, the presence of anti-PAF antibodies was significantly associated with clinical manifestations which are characteristic of APS (OR 2.6, P = 0.02). The effect was independent of IgG aCL and antibeta2GPI antibodies. CONCLUSIONS: Anti-PAF antibodies are common in APS and SLE and comprise an independent factor for the development of thrombosis. Several patients experiencing thromboses have anti-PAF antibodies without other antiphospholipid specificities.en
heal.journalNameEur J Clin Investen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
There are no files associated with this item.
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons